Literature DB >> 22848284

Expression of VEGF and MMP-9 and MRI imaging changes in cerebral glioma.

Yang Liu1, Yang Zhou, Xiu-Shi Zhang, Bao-Zhong Shen.   

Abstract

The purpose of the present study was to investigate the association of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) expression with the histopathological grading of tumors in cerebral glioma. A total of 45 patients with pathologically confirmed cerebral glioma were divided into two groups: a low-grade group (grades I and II, 21 cases) and a high-grade group (grades III and IV, 24 cases). Immunohistochemical staining of tumor samples showed the percentages of tumors expressing VEGF and MMP-9 in the high-grade group to be 95.83 and 75%, respectively, significantly higher than those of the low-grade group (66.67 and 23.81%, P<0.05 and P<0.01, respectively). The magnetic resonance imaging (MRI) results indicated that the peripheral edema index (EI), enhancement percentage (EP), and the maximum diameter of the tumor in the high-grade group were significantly higher than those in the low-grade group (P<0.05, P<0.01, and P<0.05). Moreover, the expression of VEGF and MMP-9 was positively correlated with EI, EP and the maximum diameter of the tumor (P<0.05). Therefore, VEGF and MMP-9 expression were correlated to the invasion of glioma. The association of their expression levels with EI, EP and the maximum tumor diameter indicates that these markers may be used to estimate tumor malignancy for future clinical diagnosis and treatment.

Entities:  

Year:  2011        PMID: 22848284      PMCID: PMC3406497          DOI: 10.3892/ol.2011.384

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  18 in total

Review 1.  The use of immunohistochemistry in liver tumors.

Authors:  Elaine S Chan; Matthew M Yeh
Journal:  Clin Liver Dis       Date:  2010-11       Impact factor: 6.126

Review 2.  Biomarkers for the diagnosis of thyroid cancer.

Authors:  Kruttibas Sethi; Siddik Sarkar; Subhasis Das; Biswanarayan Mohanty; Mahitosh Mandal
Journal:  J Exp Ther Oncol       Date:  2010

Review 3.  DNA methylation in brain development and gliomagenesis.

Authors:  Joseph F Costello
Journal:  Front Biosci       Date:  2003-01-01

Review 4.  The other side of MMPs: protective roles in tumor progression.

Authors:  Michelle D Martin; Lynn M Matrisian
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

Review 5.  A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner?

Authors:  Astrid Langer
Journal:  BMC Health Serv Res       Date:  2010-10-08       Impact factor: 2.655

Review 6.  Advances in evaluation of primary brain tumors.

Authors:  Wei Chen; Daniel H S Silverman
Journal:  Semin Nucl Med       Date:  2008-07       Impact factor: 4.446

Review 7.  Glioblastoma in adults.

Authors:  Alba A Brandes; Alicia Tosoni; Enrico Franceschi; Michele Reni; Gemma Gatta; Charles Vecht
Journal:  Crit Rev Oncol Hematol       Date:  2008-04-03       Impact factor: 6.312

8.  Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.

Authors:  Michael Weller; Jörg Felsberg; Christian Hartmann; Hilmar Berger; Joachim P Steinbach; Johannes Schramm; Manfred Westphal; Gabriele Schackert; Matthias Simon; Jörg C Tonn; Oliver Heese; Dietmar Krex; Guido Nikkhah; Torsten Pietsch; Otmar Wiestler; Guido Reifenberger; Andreas von Deimling; Markus Loeffler
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

9.  Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme--a dosimetric comparison.

Authors:  Marc D Piroth; Michael Pinkawa; Richard Holy; Gabriele Stoffels; Cengiz Demirel; Charbel Attieh; Hans J Kaiser; Karl J Langen; Michael J Eble
Journal:  Radiat Oncol       Date:  2009-11-23       Impact factor: 3.481

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  5 in total

1.  Tumor suppressor PDCD4 inhibits NF-κB-dependent transcription in human glioblastoma cells by direct interaction with p65.

Authors:  Soon-Kyung Hwang; Alyson R Baker; Matthew R Young; Nancy H Colburn
Journal:  Carcinogenesis       Date:  2014-01-11       Impact factor: 4.944

2.  The Clinical Utility of Matrix Metalloproteinase 9 in Evaluating Pathological Grade and Prognosis of Glioma Patients: A Meta-Analysis.

Authors:  Xiangshan Yang; Shunzeng Lv; Yuting Liu; Daotang Li; Ranran Shi; Zhenyu Tang; Jianzhen Fan; Zhongfa Xu
Journal:  Mol Neurobiol       Date:  2014-08-10       Impact factor: 5.590

3.  Specific Preoperative Dynamic Contrast-Enhanced MRI Semi-quantitative Markers Can Correlate With Vascularity in Specific Areas of Glioblastoma Tissue and Predict Recurrence.

Authors:  Mohammed A Azab; Sherief Ghozy; Sherif F Hassanein; Ahmed Y Azzam
Journal:  Cureus       Date:  2021-06-08

4.  All-trans retinoic acid upregulates VEGF expression in glioma cells in vitro.

Authors:  Chen Liang; Shiwen Guo; Ling Yang
Journal:  J Biomed Res       Date:  2012-12-19

5.  Cerebrospinal fluid matrix metalloproteinases are elevated in cerebral adrenoleukodystrophy and correlate with MRI severity and neurologic dysfunction.

Authors:  Kathryn A Thibert; Gerald V Raymond; David R Nascene; Weston P Miller; Jakub Tolar; Paul J Orchard; Troy C Lund
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.